What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
Where is Novavax's stock going? Where will Novavax's stock price be in 2017?
9 brokers have issued 1 year price objectives for Novavax's shares. Their forecasts range from $1.00 to $25.00. On average, they anticipate Novavax's stock price to reach $6.41 in the next twelve months.
When will Novavax announce their earnings?
Novavax is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (1/21/2017)
Cantor Fitzgerald analysts commented, "RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus." (1/12/2017)
Piper Jaffray Companies analysts commented, "So, Now What?" (9/16/2016)
Who owns Novavax stock?
Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (7.82%), State Street Corp (7.36%), Franklin Resources Inc. (2.02%), Eventide Asset Management LLC (0.53%), Alden Global Capital LLC (0.24%) and Royce & Associates LP (0.20%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rajiv I Modi and Stanley C Erck.
Who sold Novavax stock? Who is selling Novavax stock?
Novavax's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Eventide Asset Management LLC, Oxford Asset Management, Royce & Associates LP, Commerzbank Aktiengesellschaft FI, Brown Advisory Inc. and Frontier Capital Management Co. LLC. Company insiders that have sold Novavax stock in the last year include Gary C Evans and Stanley C Erck.
Who bought Novavax stock? Who is buying Novavax stock?
Novavax's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Alden Global Capital LLC, Renaissance Technologies LLC, Perceptive Advisors LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck.
How do I buy Novavax stock?
Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Novavax stock cost?
One share of Novavax stock can currently be purchased for approximately $1.51.